Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767520 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00767520 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 155 participants.
The verdict
NCT00767520, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI).
Interventions
- DRUG Exemestane + Dasatinib
- DRUG Exemestane + Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00767520
The ClinicalTrials.gov registry entry for NCT00767520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane + Dasatinib is the first listed.
NCT00767520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00767520 about?
NCT00767520 is a clinical study titled "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer". The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI...
What is the current status of trial NCT00767520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2009-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00767520?
The interventions under investigation include: Exemestane + Dasatinib (DRUG), Exemestane + Placebo (DRUG).
Who is sponsoring clinical trial NCT00767520?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.